PDCD1 and neoplasm: One preclinical study showed that the antitumor effect of anti-PD-1 therapy required the presence of PD-1loCD8+ T cells before treatment and decreased frequencies of tumor-infiltrating PD-1+CD8+ T cells below a threshold after the anti-PD-1 therapy (24).